CoChat

Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials

Bai, Shuang, Guo, Wenliang, Feng, Yangyang, Deng, Hong, Li, Gaigai, Nie, Hao, Guo, Guangyu, Yu, Haihan, Ma, Yang, Wang, Jiahui, Chen, Shiling, Jing, Jie, Yang, Jingfei, Tang, Yingxin, Tang, Zhouping · 2020 · Journal of Neurology, Neurosurgery & Psychiatry

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

Abstract

Objectives: To systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders. Methods: We searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline to endpoint. Secondary outcomes included response and remission rates and quality of life (QoL). Safety was evaluated by incidence of classified adverse events. Heterogeneity was examined using the I 2 and Q statistic. Pooled standard mean differences (SMDs) and risk ratios (RRs) were calculated. Subgroup meta-analyses were conducted based on type of treatment, type of anti-inflammatory agents, sex, sponsor type and quality of studies. Results: Thirty RCTs with 1610 participants were included in the quantitative analysis. The overall analysis pooling from 26 of the RCTs suggested that anti-inflammatory agents reduced depressive symptoms (SMD −0.55, 95% CI −0.75 to −0.35, I 2=71%) compared with placebo. Higher response (RR 1.52, 95% CI 1.30 to 1.79, I 2=29%) and remission rates (RR 1.79, 95% CI 1.29 to 2.49, I 2=41%) were seen in the group receiving anti-inflammatory agents than in those receiving placebo. Subgroup analysis showed a greater reduction in symptom severity in both the monotherapy and adjunctive treatment groups. Subgroup analysis of non-steroidal anti-inflammatory drugs, omega-3 fatty acids, statins and minocyclines, respectively, disclosed significant antidepressant effects for major depressive disorder (MDD). For women-only trials, no difference in changes of depression severity was found between groups. Subanalysis stratified by sponsor type and study quality led to the same outcomes in favour of anti-inflammatory agents in both subgroups. Changes of QoL showed no difference between the groups. Gastrointestinal events were the only significant differences between groups in the treatment periods. Conclusions: Results of this systematic review suggest that anti-inflammatory agents play an antidepressant role in patients with MDD and are reasonably safe.

Overview

Integrity signals

Registry

Crossref · 10.1136/jnnp-2019-320912

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Research works printed but not linked: 1

  1. 2008, Tolerability of modern antidepressants, J Clin Psychiatry, 69 Suppl E1, 8

Cited by

See all 244

Metadata

Authors
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., Chen, S., Jing, J., Yang, J., Tang, Y., & Tang, Z.
Affiliations
  • Tongji Hospital (CN)
  • Huazhong University of Science and Technology (CN)
Corresponding author
Tang, Zhouping
Venue
Journal of Neurology, Neurosurgery & Psychiatry
Publisher
BMJ
Published
2019-10-28
Volume
91
Issue
1
Pages
21-32
ISSN
  • 0022-3050 (ISSN-L)
  • 1468-330X
OpenAlex
W2982529276
Cited by
235
References
46
Citations by year
2026: 25 · 2025: 42 · 2024: 35 · 2023: 42 · 2022: 39 · 2021: 31 · 2020: 20
FWCI
2.89
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
the National Natural Science Foundation of China (81873750)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
major depressive disorder, anti-inflammatory agents, antidepressant efficacy, treatment safety, nonsteroidal anti-inflammatory drugs, omega-3 fatty acids, statins, minocycline, quality of life, gastrointestinal adverse effects, sex differences
MeSH terms
Anti-Inflammatory Agents, Anti-Inflammatory Agents, Non-Steroidal, Major Depressive Disorder, Depressive Disorder, Major, Humans, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. https://app.cochat.ai/papers/10.1136/jnnp-2019-320912
The paper
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., Chen, S., Jing, J., Yang, J., Tang, Y., & Tang, Z. (2020). Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp-2019-320912

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.